ArticleJournal of virology2020
Identification of Common CD8
Open access · hybridAbstract read
In one paragraph
Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- A systematic review of the immuno-inflammatory dysfunction secondary to viral hemorrhagic fevers; Ebola and Lassa fever.PLoS neglected tropical diseases · 2025Pooled it
- Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.Frontiers in immunology · 2025Trial
- Decoding the human CD4Cell reports. Medicine · 2026Article
- A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential.Current pharmaceutical biotechnology · 2026Article
- Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.The Journal of general virology · 2025Article
- Robust polyfunctional CD8The Journal of general virology · 2025Article
- Expansion of myeloid suppressor cells and suppression of Lassa virus-specific T cells during fatal Lassa fever.PLoS pathogens · 2025Article
- Article
- The Adaptive Immune Response againstViruses · 2024Review
- Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination.Science advances · 2023Article
- Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors.PLoS neglected tropical diseases · 2022Article
- The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid.Viruses · 2022Review
- Adjuvants Differentially Modulate the Immunogenicity of Lassa Virus Glycoprotein Subunits in Mice.Frontiers in tropical diseases · 2022Article
- Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans.Viruses · 2021Article
- Article
- Article
- Ebola-Specific CD8+ and CD4+ T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae.The Journal of infectious diseases · 2020Article
- Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 8 institutions in 3 countries.
Saori SakabeViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Jessica N HartnettDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Nhi NgoViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Augustine GobaViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Mambu MomohViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
John Demby SandiViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Lansana KannehViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Beatrice CubittViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Selma D GarciaViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Brian C WareViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Dylan KotliarFAS Center for Systems Biology, Harvard University, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Refugio Robles-SikisakaViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Karthik GangavarapuDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Luis M BrancoZalgen Labs, Germantown, Maryland, USA.
Philomena EromonAfrican Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemers University, Ede, Nigeria.
Ikponmwosa OdiaInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Ephraim Ogbaini-EmovonInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Onikepe FolarinAfrican Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemers University, Ede, Nigeria.
Sylvanus OkogbeninInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Peter O OkokhereInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Christian HappiAfrican Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemers University, Ede, Nigeria.
Pardis C SabetiFAS Center for Systems Biology, Harvard University, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Kristian G AndersenViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Robert F GarryDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Juan Carlos de la TorreViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Donald S GrantViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
John S SchieffelinDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Michael B A OldstoneViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
Brian M SullivanViral Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA bsully@scripps.edu.
Scripps Research Institute · USIrrua Specialist Teaching Hospital · NGRedeemer's University · NGUniversity of Sierra Leone · SLBroad Institute · USMinistry of Health and Sanitation · SLTulane University · USZalgen (United States) · US
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MSpecific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0MMechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2014 to 2018
$29.6MStructure-based design of novel Lassa virus glycoproteins for vaccine developmentR01AI132244 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2017 to 2021
$6.5MAntibody immunotherapeutics for biodefense against Lassa virusR01AI104621 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2013 to 2017
$5.8MPreclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktailR01AI132223 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2017 to 2021
$5.7MProject 2. Expansion of Clinical Research Capacity at Kenema Government HospitalU19AI115589 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2015 to 2019
$3.6MClinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus DiseaseR01AI123535 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FISCHER, WILLIAM, WOHL, DAVID A · 2017 to 2021
$3.3MNIAID NIH HHS HHSN272201400048CNIAID NIH HHS R01 AI104621NIAID NIH HHS R01 AI123535NIAID NIH HHS R01 AI132223NIAID NIH HHS R01 AI132244NIAID NIH HHS U19 AI109762NIAID NIH HHS U19 AI115589NIAID NIH HHS U19 AI142790NIGMS NIH HHS T32 GM007753
Abstract
Early and robust T cell responses have been associated with survival from Lassa fever (LF), but the Lassa virus-specific memory responses have not been well characterized. Regions within the virus surface glycoprotein (GPC) and nucleoprotein (NP) are the main targets of the Lassa virus-specific T cell responses, but, to date, only a few T cell epitopes within these proteins have been identified. We identified GPC and NP regions containing T cell epitopes and HLA haplotypes from LF survivors and used predictive HLA-binding algorithms to identify putative epitopes, which were then experimentally tested using autologous survivor samples. We identified 12 CD8-positive (CD8
Indexed as
AdolescentAmino Acid SequenceAnimalsAntibodies, ViralAntigens, ViralCD8-Positive T-LymphocytesChildEpitopes, T-LymphocyteFemaleGenes, ReporterGreen Fluorescent ProteinsHaplotypesHLA-DQ AntigensHost-Pathogen InteractionsHumansImmune SeraAntibodies, ViralAntigens, Viralenhanced green fluorescent proteinEpitopes, T-LymphocyteGreen Fluorescent ProteinsHLA-DQ AntigensImmune SeraNucleoproteinsViral Envelope ProteinsarenavirusepitopesLassa feverLassa virusmemory T cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.